# Pathfinder Bancorp, Inc.: financial statements, quarterly

PBHC · Nasdaq · CIK 1609065 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pbhc.md) · [Financials](/companies/pbhc/financials.md) · [Filings](/companies/pbhc/filings.md) · [Insiders](/companies/pbhc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pbhc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Interest expense | $k | [7,611](/filings/0000950170-23-063449.md) | [9,169 d](/filings/0000950170-24-035248.md) | [9,210](/filings/0000950170-24-060110.md) | [9,542](/filings/0000950170-24-097025.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | [573](/filings/0000950170-24-126921.md) | [590 d](/filings/0000950170-25-047820.md) | [532](/filings/0000950170-25-072602.md) | [481](/filings/0000950170-25-108856.md) | [(1,173)](/filings/0001193125-25-282280.md) | [492 d](/filings/0001193125-26-132075.md) | [744](/filings/0001193125-26-226649.md) | [7.0](/filings/0001193125-26-349125.md) | [46.0](/filings/0001193125-25-282280.md) | [(2,957) d](/filings/0001193125-26-132075.md) | [530](/filings/0001193125-26-226649.md) | [585](/filings/0001193125-26-349125.md) |
| Net income | $k | [2,176](/filings/0000950170-24-126921.md) | [2,536 d](/filings/0000950170-25-047820.md) | [2,120](/filings/0000950170-25-072602.md) | [2,000](/filings/0000950170-25-108856.md) | [(4,644)](/filings/0001193125-25-282280.md) | [3,907 d](/filings/0001193125-26-132075.md) | [2,974](/filings/0001193125-26-226649.md) | [31.0](/filings/0001193125-26-349125.md) | [626](/filings/0001193125-25-282280.md) | [(5,564) d](/filings/0001193125-26-132075.md) | [2,413](/filings/0001193125-26-226649.md) | [2,668](/filings/0001193125-26-349125.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | [0.41](/filings/0000950170-25-108856.md) | [0.41](/filings/0001193125-25-282280.md) | not reported | not reported | [0.47](/filings/0000950170-25-108856.md) | [0.47](/filings/0001193125-25-282280.md) | not reported | not reported | not reported |
| Basic EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: not reported

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total assets | $m | [1,401](/filings/0000950170-23-063449.md) | [1,466](/filings/0000950170-25-047820.md) | [1,454](/filings/0000950170-24-060110.md) | [1,446](/filings/0000950170-24-097025.md) | [1,483](/filings/0000950170-24-126921.md) | [1,475](/filings/0001193125-26-132075.md) | [1,495](/filings/0000950170-25-072602.md) | [1,505](/filings/0000950170-25-108856.md) | [1,472](/filings/0001193125-25-282280.md) | [1,427](/filings/0001193125-26-349125.md) | [1,422](/filings/0001193125-26-226649.md) | [1,493](/filings/0001193125-26-349125.md) |
| Total liabilities | $m | [1,286](/filings/0000950170-23-063449.md) | [1,346](/filings/0000950170-25-047820.md) | [1,331](/filings/0000950170-24-060110.md) | [1,322](/filings/0000950170-24-097025.md) | [1,362](/filings/0000950170-24-126921.md) | [1,353](/filings/0001193125-26-132075.md) | [1,370](/filings/0000950170-25-072602.md) | [1,381](/filings/0000950170-25-108856.md) | [1,346](/filings/0001193125-25-282280.md) | [1,304](/filings/0001193125-26-349125.md) | [1,298](/filings/0001193125-26-226649.md) | [1,367](/filings/0001193125-26-349125.md) |
| Long-term debt | $m | [53.9](/filings/0000950170-23-063449.md) | [49.9](/filings/0000950170-25-047820.md) | [45.9](/filings/0000950170-24-060110.md) | [45.9](/filings/0000950170-24-097025.md) | [39.8](/filings/0000950170-24-126921.md) | [27.1](/filings/0001193125-26-132075.md) | [17.6](/filings/0000950170-25-072602.md) | [21.0](/filings/0000950170-25-108856.md) | [18.7](/filings/0001193125-25-282280.md) | [14.1](/filings/0001193125-26-349125.md) | [12.4](/filings/0001193125-26-226649.md) | [8.4](/filings/0001193125-26-349125.md) |
| Short-term borrowings | $m | [56.7](/filings/0000950170-23-063449.md) | [126](/filings/0000950170-25-047820.md) | [91.6](/filings/0000950170-24-060110.md) | [128](/filings/0000950170-24-097025.md) | [60.3](/filings/0000950170-24-126921.md) | [61.0](/filings/0001193125-26-132075.md) | [27.0](/filings/0000950170-25-072602.md) | [75.5](/filings/0000950170-25-108856.md) | [38.0](/filings/0001193125-25-282280.md) | [44.0](/filings/0001193125-26-349125.md) | [15.0](/filings/0001193125-26-226649.md) | [125](/filings/0001193125-26-349125.md) |
| Shareholders' equity | $m | [114](/filings/0000950170-23-063449.md) | [119](/filings/0000950170-25-047820.md) | [122](/filings/0000950170-24-060110.md) | [123](/filings/0000950170-24-097025.md) | [120](/filings/0000950170-24-126921.md) | [121](/filings/0001193125-26-132075.md) | [125](/filings/0000950170-25-072602.md) | [124](/filings/0000950170-25-108856.md) | [126](/filings/0001193125-25-282280.md) | [122](/filings/0001193125-26-349125.md) | [124](/filings/0001193125-26-226649.md) | [126](/filings/0001193125-26-349125.md) |

- Cash and equivalents: not reported
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [5.1 d](/filings/0000950170-24-126921.md) | [8.4 d](/filings/0000950170-25-047820.md) | [0.5](/filings/0000950170-25-072602.md) | [1.5 d](/filings/0000950170-25-108856.md) | [11.8 d](/filings/0001193125-25-282280.md) | [(2.7) d](/filings/0001193125-26-132075.md) | [5.7](/filings/0001193125-26-226649.md) | [(3.7) d](/filings/0001193125-26-349125.md) | [7.0 d](/filings/0001193125-25-282280.md) | [2.7 d](/filings/0001193125-26-132075.md) | [(0.2)](/filings/0001193125-26-226649.md) | [2.3 d](/filings/0001193125-26-349125.md) |
| Capital expenditure | $m | [1.0 d](/filings/0000950170-24-126921.md) | [0.3 d](/filings/0000950170-25-047820.md) | [0.2](/filings/0000950170-25-072602.md) | [0.9 d](/filings/0000950170-25-108856.md) | [0.5 d](/filings/0001193125-25-282280.md) | [0.4 d](/filings/0001193125-26-132075.md) | [0.6](/filings/0001193125-26-226649.md) | [0.2 d](/filings/0001193125-26-349125.md) | [0.1 d](/filings/0001193125-25-282280.md) | [0.3 d](/filings/0001193125-26-132075.md) | [0.2](/filings/0001193125-26-226649.md) | [0.2 d](/filings/0001193125-26-349125.md) |
| Dividends paid | $m | [0.4 d](/filings/0000950170-24-126921.md) | [0.4 d](/filings/0000950170-25-047820.md) | [0.4](/filings/0000950170-25-072602.md) | [0.5 d](/filings/0000950170-25-108856.md) | [0.5 d](/filings/0001193125-25-282280.md) | [0.5 d](/filings/0001193125-26-132075.md) | [0.1](/filings/0001193125-26-226649.md) | [0.8 d](/filings/0001193125-26-349125.md) | [0.5 d](/filings/0001193125-25-282280.md) | [0.5 d](/filings/0001193125-26-132075.md) | [0.1](/filings/0001193125-26-226649.md) | [0.8 d](/filings/0001193125-26-349125.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: not reported

## Shares

| Line item | Unit | Q2 FY2017 (2017-06-30) | Q3 FY2017 (2017-09-30) | Q1 FY2018 (2018-03-31) | Q2 FY2018 (2018-06-30) | Q3 FY2018 (2018-09-30) | Q1 FY2019 (2019-03-31) | Q2 FY2019 (2019-06-30) | Q3 FY2019 (2019-09-30) | Q1 FY2020 (2020-03-31) | Q2 FY2020 (2020-06-30) | Q3 FY2020 (2020-09-30) | Q1 FY2021 (2021-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [4,183](/filings/0001564590-18-021248.md) | [4,198](/filings/0001564590-18-029224.md) | [4,236](/filings/0001564590-19-019130.md) | [4,256](/filings/0001564590-19-031063.md) | [4,279](/filings/0001564590-19-042788.md) | [4,308](/filings/0001564590-20-027590.md) | [4,443](/filings/0001564590-20-039872.md) | [4,579](/filings/0001564590-20-054218.md) | [4,607](/filings/0001564590-21-028281.md) | [4,639](/filings/0001564590-20-039872.md) | [4,650](/filings/0001564590-20-054218.md) | [4,442](/filings/0001564590-21-028281.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,553,886 at 2021-05-17, from the cover of the [10-Q filed 2021-05-17](/filings/0001564590-21-028281.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.